Ampersand Capital Partners announced today that it has completed the acquisition of Pacific Biomarkers and merged it with existing portfolio company NEOMED-LABS. This merger brings together two leading bioanalytical CROs with unrivaled credentials in immunology and particular expertise in assay development, custom biomarker validation, and high-throughput clinical sample testing.
Based in Seattle and founded in 1989, Pacific Biomarkers provides specialty biomarker development and central laboratory testing services for the pharmaceutical and biotech markets. The company is a full-service bioanalytical laboratory, capable of supporting pharma sponsors with efficacy and drug safety related testing from preclinical through Phase IV clinical studies.
“The merger of NEOMED-LABS and Pacific Biomarkers creates an expanded business with a broad set of capabilities, allowing the combined entity to better serve its customers,” said Benoit Bouche, President and Chief Executive Officer of NEOMED-LABS, who will serve as CEO of the combined entity. “We are excited to bring two world-class laboratories together and build a center of excellence for clinical immunology and specialty biomarker testing services.”
Amar Sethi, current President and CSO of Pacific Biomarkers who will serve as President and Chief Medical Officer of the combined business added: “I am very pleased with the closing of this strategic transaction. Pacific Biomarkers has been providing industry-leading testing services to customers for nearly 30 years and this merger positions us to further accelerate our growth as part of a larger business with more resources. I am highly confident that this combined business will be well positioned to serve a global base of customers.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Ampersand’s goal with our original investment in NEOMED-LABS earlier this year was to build a world class leader in clinical immunology lab services, and this merger furthers that goal,” stated Eric Lev, Partner at Ampersand. “Ampersand looks forward to working with the management team in the next phase of growth for the combined company to provide industry-leading clinical laboratory testing services for the pharma, IVD, and biotech markets.”
Date: November 26, 2018
Source: Cision
